Study: Bekker 2024, New England Journal of Medicine
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Citation
Bekker LG, Das M, Abdool Karim Q, Ahmed K et al (2024). New England Journal of Medicine. PubMed id 39046157.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- HIV prevention, testing and PrEP Tier A strong
A 5,338 HIV-negative adolescent girls and young women in South Africa and Uganda (n=5338)
Phase 3 randomised, double-blind, controlled trial (PURPOSE 1) of twice-yearly lenacapavir, daily F/TAF or daily F/TDF.
55 HIV infections occurred: none among 2,134 on lenacapavir (0 per 100 person-years; 95% CI 0.00 to 0.19), 39 among 2,136 on F/TAF (2.02) and 16 among 1,068 on F/TDF (1.69). Background incidence in the screened population was 2.41 per 100 person-years. Lenacapavir was significantly lower than background and than F/TDF; F/TAF did not differ significantly from background. The authors note gaps in uptake, adherence and persistence of PrEP among cisgender women.
As recorded in this card: Bekker LG, Das M, Abdool Karim Q, Ahmed K et al (2024), New England Journal of Medicine, [primary]
Note: African adolescent girls and young women; the abstract was cut off before safety and adherence details.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.